A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Table 5 Investigator-evaluated assessment of best overall response

	Ganetespib	Ganetespib	Ganetespib	Overall
	7-114 mg/m²	150-216 mg/m²	259 mg/m²	response
	n = 25 (%)	n = 22 (%)	n = 6 (%)	n = 53 (%)
Best response^a, n (%)
Complete response	0	0	0	0
Partial response	1 (4)	0	0	1 (1.9)
Stable disease	10 (40)	11 (50)	2 (33.3)	23 (43.4)
Progressive disease	10 (40)	5 (22.7)	3 (50)	18 (34)
Non-evaluable^b	4 (16)	6 (27.3)	1 (16.7)	11 (20.8)
Disease control rate (≥ 8 weeks)^c	11 (44)	11 (50)	2 (33.3)	24 (45.3)
Disease control rate (≥ 16 weeks)^d	5 (20)	6 (27.3)	2 (33.3)	13 (24.5)

^aInitial assessment at 8 weeks from treatment start with confirmation assessment at least 4 weeks later.
^bReasons for non-evaluable patients: investigator decision (2), symptom deterioration (8) and withdrawal of informed consent (1).
^cdisease control rate: Complete and partial responses, and stable disease ≥ 8 weeks.
^ddisease control rate: Complete and partial responses, and stable disease ≥ 16 weeks.

ISSN: 1471-2407